Am Fam Physician. 2009 Feb 1;79(3):online.
to the editor: We appreciated the recent review of pharmacologic management options for adult depression, which addressed many important issues that family physicians face. Depression is a major health issue associated with morbidity and loss of productivity. In 2007, antidepressants ranked as the top class of medications dispensed in the United States, with an estimated 232.7 million antidepressant prescriptions and an estimated sale of $11.9 billion.1 However, a recent meta-analysis suggests that selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may not be more effective than placebo.2 Selective publication of positive studies appears to have greatly overstated the benefits of these drugs.3
Although we have regularly witnessed apparent benefits of SSRIs and SNRIs in patients with depression, family physicians should also recognize the limitations of data regarding these drugs and call for further research and discussion. Could the dramatic responses to antidepressant medications be a placebo effect in which providers actively listen and patients feel understood, gain insight, believe in their treatment plan, feel motivated to change their lifestyle or social situation, or perhaps some combination?4 Should we reintroduce the N-of-1 trials, in which each patient is their own “study” comparing placebo with active medication over some period of time, in order to identify the small proportion of patients who may benefit from SSRIs or SNRIs?
The majority of depression studies measure changes in depression scores that have uncertain clinical significance. Remission rates are rarely measured, and most studies are of short duration (often as little as 24 weeks of follow-up). We need to help researchers identify outcome measures that are more meaningful in the primary care setting.
Perhaps physicians should prescribe SSRIs and SNRIs only after fully disclosing to their patients that the drugs may be acting through the placebo effect and sharing the known side effects.5,6 Clearly, more research is needed. We think it is time to find out if there are better ways to treat depression.
Author disclosure: Nothing to disclose.
REFERENCESshow all references
1. 2007 U.S. Sales and Prescription Information. IMS Health Incorporated. http://www.imshealth.com/portal/site/imshealth/menuitem.a46c6d4df3db4b3d88f611019418c22a/?vgnextoid=936d9df4609e9110VgnVCM10000071812ca2RCRD&vgnextfmt=default. Accessed June 2, 2008....
2. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008;5(2):e45.
3. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358(3):252–260.
4. Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA. 2002;287(14):1840–1847.
5. Sherman R, Hickner J. Academic physicians use placebos in clinical practice and believe in the mind-body connection. J Gen Intern Med. 2008;23(1):7–10.
6. Sade RM. Placebo use in clinical practice. Report of the Council on Ethical and Judicial Affairs. CEJA Report 2-1-06. http://www.ama-assn.org/ama1/pub/upload/mm/369/ceja_recs_2i06.pdf. Accessed May 7, 2008.
in reply: We appreciate Dr. Grossman's input regarding the risk of hyponatremia with use of selective serotonin reuptake inhibitors (SSRIs) and about the use of antidepressants during pregnancy and breast feeding. The complicated issue of managing depression during pregnancy and the postpartum period is a worthy topic for a separate review.
The letter from Drs. Baghdady, Goo, and Mayer raises important concerns regarding the quality of evidence supporting the efficacy of antidepressants in patients with major depression. The number of studies on this topic is astounding. PubMed indexes 4,750 papers related to clinical trials of anti-depressive agents. However, antidepressant trials are typically industry-sponsored and short in duration. The issue of publication bias raises worrisome issues about drawing conclusions about efficacy and harms solely from published data. Although we disagree with the conclusion that antidepressants are no better than placebo, we do agree that large, well-designed, long-term studies are needed to fully elucidate when and how anti-depressants should be used.
Send letters to email@example.com, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680. Include your complete address, e-mail address, and telephone number. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors.
Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the AAFP permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.
This series is coordinated by Kenny Lin, MD, MPH, Associate Deputy Editor for AFP Online.
Copyright © 2009 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact firstname.lastname@example.org for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions